We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech

🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer! www.businesswire.com/news/home/20...

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com! 🧵👇

This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social ‪for the great conversation, and for your passion and excitement for biotech and entrepreneurship!

Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1... 🧵🧪

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

It was an honor to speak from the main stage at TED last week about our work at AI Proteins Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

Big news to share! Phil Brandish has joined our team and will lead drug development efforts at AI Proteins. Phil is a rockstar, with a stellar track record and years of experience successfully bringing molecules into the clinic at Merck and Bicycle Therapeutics.

I’m excited to share that I am now the CEO of AI Proteins @aiproteins.bsky.social! I’m grateful to continue leading this exceptional team as we build upon the strong foundation that we’ve established since launching the company in 2021. www.businesswire.com/news/home/20... 🧵👇

So, I might have ended up on the jumbotron at the Celtics game proudly wearing my @aiproteins.bsky.social colors

Mireia Solà Colom gave an incredible seminar at @bpdmc.bsky.social last week, and I'm very excited for her to share some details about what we've built at @aiproteins.bsky.social and how well our #miniproteins perform as therapeutics

So excited for my postdoc mentor David Baker giving his Nobel Prize lecture in Stockholm!!

Today, several #NobelPrize Laureates arrive in Stockholm, warmly welcomed by Hans Ellegren. Here we see David Baker stepping off the plane at Arlanda. This week is packed with inspiration, press conferences and lectures, so stay tuned! 🌟 @uofwa.bsky.social @hhmi.bsky.social #Science #AcademicSky

Exciting times at @aiproteins.bsky.social ! We are getting so close to see our drugs helping patients! www.fiercebiotech.com/biotech/bris...

and more coverage from Endpoints News @endpts.com endpts.com/bms-inks-dea...

You can read more about our exciting new collaboration with Bristol Myers Squibb in this coverage from Fierce Biotech www.fiercebiotech.com/biotech/bris...

AI Proteins is excited to partner with @bms-news.bsky.social to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes www.businesswire.com/news/home/20...

We've got some very exciting news to share! businesswire.com/news/home/20... and here's a 🧵 about the journey from academia to @aiproteins.bsky.social

There's just one meeting left in 2024, and we have a spectacular seminar by Mireia Solà Colom lined up for you! Join us at 7pm in Room 181, Building 68, MIT on Wednesday, December 11th. "De novo design of miniprotein-based natural killer cell engagers" See you there & Happy Thanksgiving! bpdmc.org

Our founder, President and CSO Chris Bahl @cdbahl.bsky.social went to the Falling Walls Science Summit last week to explain how we make #miniprotein therapeutics with unprecedented ability to control cellular behavior - you can check out the recording 👇 www.youtube.com/live/zB6-iUB...